Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
NCT04999085 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2025-02-28
Summary
Myeloma is the second most common type of blood cancer in the United States. Myeloma most commonly affects older adults. While some younger individuals do get myeloma, the average age when people are first diagnosed with myeloma is around 69 to 70.
Along with having a higher risk for myeloma, older adults have an increased chance of developing other health problems or issues. However, not everyone ages in the same way. Some older adults experience major changes in health or degree of independence at relatively younger ages, while others remain quite healthy for many years. The specific issues that develop with age can also vary from person to person. One older adult may face difficulties with vision or hearing, while another may develop memory problems.
Historically, cancer doctors have not done a very good job identifying these non-cancer issues. As a result, research has focused on better ways to systematically pick up on issues that may impact cancer outcomes or quality of life. The outgrowth of this research is assessments and questionnaires referred to as "comprehensive geriatric assessments," which evaluate the health and functionality of older adults thoroughly but efficiently. In both myeloma and other types of cancer, problems identified through geriatric assessments have been shown to predict how likely people are to develop side effects of cancer treatment and predict how long people are likely to live with cancer.
Prior research has not addressed how best to help with the issues picked up through a geriatric assessment among patients undergoing treatment for myeloma, although a number of effective interventions have been shown to benefit older adults with similar problems in other settings. Therefore, the current study will test a strategy of systematically screening older adults undergoing myeloma treatment for geriatric-assessment-related deficits and referring participants to appropriate services and resources. The geriatric assessment in this study includes tests of mobility, memory, vision, hearing, and nutrition as well as questions about symptoms and social support. Individuals who have deficits in one of these areas will be referred to relevant services and resources such as physical therapy, a pharmacist, or the cancer center support program. They will then repeat the same assessment three months later, and the results will be compared to their original assessment to see if the deficit has improved, with particular attention to mobility and social support.
Conditions
- Multiple Myeloma
- Myeloma
- Disability Physical
- Disabilities Multiple
Interventions
- OTHER
-
Supportive care interventions
Subjects will be referred to specialists and/or supportive care interventions based on issues/deficits identified on a baseline geriatric assessment. These interventions will be selected based on deficits or problems identified on baseline assessments. These include referral to physical/occupational therapy for those with physical deficits (Activities of Daily Living impairment, Instrumental Activities of Daily Living impairment, Timed Up and Go, or falls), to optometry/ophthalmology (for visual impairment), to audiology (for hearing impairment), to pharmacist (for polypharmacy), and to cancer center support program (for Mental Health Index 13 criteria).
Sponsors & Collaborators
-
Conquer Cancer Foundation
collaborator OTHER -
UNC Lineberger Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Christopher E Jensen, MD · University of North Carolina, Chapel Hill
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-01
- Primary Completion
- 2023-08-04
- Completion
- 2023-08-04
Countries
- United States
Study Locations
More Related Trials
-
Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years
NCT00546988 ·Status: UNKNOWN ·Phase: PHASE3
-
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
NCT01109407 ·Status: TERMINATED
-
Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma
NCT05355987 ·Status: COMPLETED ·Phase: NA
-
Connect® MM- The Multiple Myeloma Disease Registry
NCT01081028 ·Status: TERMINATED
-
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
NCT00006184 ·Status: COMPLETED ·Phase: PHASE2
-
Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)
NCT05276622 ·Status: TERMINATED
-
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
NCT01208662 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
NCT03777306 ·Status: COMPLETED ·Phase: NA
-
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00995059 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.
NCT02063113 ·Status: TERMINATED ·Phase: NA
-
Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace
NCT02898064 ·Status: COMPLETED ·Phase: NA
-
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
NCT06182774 ·Status: RECRUITING ·Phase: PHASE3
-
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
NCT01191060 ·Status: COMPLETED ·Phase: PHASE3
-
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
NCT03224507 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
NCT03742297 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
NCT06212323 ·Status: RECRUITING
-
Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
NCT02308280 ·Status: COMPLETED ·Phase: PHASE2
-
Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation
NCT03508765 ·Status: COMPLETED ·Phase: NA
-
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
NCT02728102 ·Status: COMPLETED ·Phase: PHASE2
-
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
NCT01849783 ·Status: COMPLETED ·Phase: PHASE2
-
Familial Dysglobulinemia
NCT02853214 ·Status: COMPLETED ·Phase: NA
-
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
NCT00002556 ·Status: COMPLETED ·Phase: PHASE3
-
Imageguided Theranostics in Multiple Myeloma
NCT02403102 ·Status: COMPLETED
-
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
NCT00003153 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
NCT00114101 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3